Stay updated on Efgartigimod in Post-COVID-19 POTS Clinical Trial
Sign up to get notified when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.

Latest updates to the Efgartigimod in Post-COVID-19 POTS Clinical Trial page
- Check7 days agoChange DetectedThe NIH transition announcement banner was removed from the top of the page.SummaryDifference1%

- Check14 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0. The study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check28 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check35 days agoChange DetectedThe error page footer now shows revision v3.7.1 instead of v3.7.0; the page remains a 403 Forbidden response.SummaryDifference0.2%

- Check55 days agoChange DetectedThe study page now shows a 403 Forbidden error, replacing the study record content; this indicates an access-related issue that blocks viewing the study details.SummaryDifference19%

- Check77 days agoChange DetectedThe page now shows Revision: v3.6.6, replacing the previous v3.6.5. This indicates a small software/content update to the page.SummaryDifference0.1%

Stay in the know with updates to Efgartigimod in Post-COVID-19 POTS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.